Biomark Diagnostics Full Year 2023 Earnings: CA$0.022 loss per share (vs CA$0.02 loss in FY 2022)

Biomark Diagnostics (FRA:20B) Full Year 2023 Results

Key Financial Results

• Revenue: CA$153.5k (up 249% from FY 2022).
• Net loss: CA$1.84m (loss widened by 27% from FY 2022).
• CA$0.022 loss per share (further deteriorated from CA$0.02 loss in FY 2022).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Biomark Diagnostics shares are up 5.1% from a week ago.

Risk Analysis

We should say that we've discovered 6 warning signs for Biomark Diagnostics (5 don't sit too well with us!) that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.